To investigate changes in the proportion of patients with age-related macular degeneration (AMD) visiting hospitals and to investigate factors associated with AMD, treatments, and medical expenses, as well as the outlook for AMD in Japan using a large health insurance database.

USH2A mutations are an important cause of retinitis pigmentosa (RP) with or without congenital sensorineural hearing impairment. We studied genotype–phenotype correlations and compared visual prognosis in Usher syndrome type IIa and nonsyndromic RP.

Patients with iris defects suffer from severe visual impairment, especially increased glare sensitivity and cosmetic disturbances. This constitutes a great psychological strain for those patients. Until recently, possible treatment options were iris print contact lenses, sunglasses, and simple iris prostheses. The aim of this study was to investigate structural and functional outcome parameters and patient satisfaction after implantation of this new artificial iris prosthesis.

To provide 2-year results comparing anti–vascular endothelial growth factor (VEGF) agents for center-involved diabetic macular edema (DME) using a standardized follow-up and retreatment regimen.

In our randomized trial comparing part-time patching with observation for intermittent exotropia in children 12 to 35 months of age, we reported the incidence of deterioration of intermittent exotropia for each group over a 6-month period.1 We did not measure orbital parameters and we are therefore unable to comment on any association between intermittent exotropia and orbital anatomy. The potential effects of differences in orbital anatomy between patients, or potential effects of longitudinal changes in orbital anatomy, were minimized by our random allocation of treatment assignments in this study.

We read with interest the article titled “Vitreomacular interface after anti-vascular endothelial growth factor injections in neovascular age-related macular degeneration” by Veloso et al.1 The investigators evaluated the incidence of posterior vitreous detachment (PVD) induced by intravitreal injections of anti-vascular endothelial growth factor agents in cases of neovascular age-related macular degeneration.